Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 5/20 | 0.97 |
| ▸ | DHCR7 | Q9UBM7 | 5/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17007504 | 0.98 | EBP (1.00) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL17007435 | 0.98 | EBP (1.00) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL17007433 | 0.88 | DHCR7 (1.00) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL17007476 | 0.88 | EBP (0.77) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL17007487 | 0.87 | EBP (0.75) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL22032981 | 0.87 | EBP (0.78) | EBPDHCR7ALDH1A1EPHX2NPSR1 | |
| Hydrochloric Acid SCHEMBL17007426 | 0.87 | DHCR7 (0.97) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL17007491 | 0.85 | EBP (0.72) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL17007407 | 0.85 | EBP (0.74) | EBPDHCR7KDM4EALDH1A1EPHX2 | |
| SCHEMBL19823068 | 0.85 | EBP (0.74) | EBPDHCR7KDM4EALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11344511-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| CN-105873913-B | Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins | 得克萨斯系统大学评议会 | 2019-12-03 | — | — | CN | disclosed |
| US-20190269670-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2019-09-05 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| CN-105873913-A | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | 得克萨斯系统大学评议会 | 2016-08-17 | — | — | CN | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | EBP 1178/4885DHCR7 1996/4885KDM4E 2086/4885 |
| US-11344511-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | EBP 8/4885DHCR7 19/4885KDM4E 2290/4885 |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | EBP 1178/4885DHCR7 1996/4885KDM4E 2086/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | EBP 4598/4885DHCR7 3774/4885KDM4E 1361/4885 |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | SREBF1, SREBF2, EBPL | EBP 4/4885DHCR7 54/4885KDM4E 2393/4885 |
| US-20190269670-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | EBP 8/4885DHCR7 19/4885KDM4E 2290/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | EBP 1178/4885DHCR7 1996/4885KDM4E 2086/4885 |
| US-20230000798-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | EBP 8/4885DHCR7 19/4885KDM4E 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.